Louis Haenel, IV, DO Endocrinology. Terminology Lipodystrophy Lipoatrophy Lipohypertrophy HIV HAART (Highly Active Anti-Retroviral Therapy)

Slides:



Advertisements
Similar presentations
Christine M. Stanley, B.A. † Drago Turčinov, M.D.*
Advertisements

Ronald A. Codario, MD Assistant Clinical Professor of Medicine
Immune Activation/Inflammation and HIV Disease Prof. Georg Behrens Department for Clinical Immunology and Rheumatology Hannover Medical School Germany.
LIPID METABOLISM IN THYROID DISEASE
What Is New in HIV Infection? Journal of AAFP February 15, 2014 Volume 89, Number 4 Today is 3/26/14, and my name is Isaac Engholm, DO.
Body Composition and Metabolic Changes in Antiretroviral-Naïve HIV-Infected Patients Randomized to Didanosine and Stavudine (ddI+d4T) vs. Abacavir and.
Metabolic Complications of HIV Dr Lou Haenel, Jr Endocrinology 12/10.
Mutations and Genetic Diseases DNAmRNAAAProperties of AAAffect CTCGAGGluHydrophilic/AcidicNormal CTTGAAGluHydrophilic/AcidicNone (Silent) CTAGAUAspHydrophilic/AcidicNone.
HIV/AIDS and Nutrition Jeanne Garber MS,RD,LN Yellowstone City-County Health Department.
Vaccines and Antivirals. Clinical Use of Interferon Therefore they have been used in the treatment of cancers of various types. Therefore they have been.
1 Inhibitors of Other Viruses A. RIBAVIRIN Ribavirin (Virazole) is a nucleoside analogue in which a triazolecarboxamide moiety is substituted on place.
MCB 135K: Discussion.
HIV Structure, Lifecycle, and Replication
Introduction: Dyslipidemia in HIV - May arise from viral infection, antiretroviral treatment and changes in body composition 1 - Is a key metabolic abnormality.
Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies.
Antivirals for HIV Yasir Waheed, PhD. Some HIV Facts HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS HIV belongs to the retrovirus.
Session 3: Nutrition and HIV Medications
Case Presentation Managing treatment side effects in the correctional environment Stephen Tabet, MD, MPH University of Washington Division of Infectious.
The Antihyperlipidemic Medications l Classifications of Lipoproteins – Chylomicrons l Formed in the mucosal cells of the gut l Protein coated dietary lipids.
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
Amber Leon Jeanine Mills Erin Prasad Nutrition Assessment and Therapy 1 Winter 2012.
Plate 87 Acquired Immune Deficiency Syndrome (AIDS)
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
S.Collins HIV i-Base UK-CAB November 2005 UK-CAB November 2005 Feedback from 7th Lipodystrophy Workshop November, Dublin.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 93 Antiviral Agents II: Drugs for HIV Infection and Related.
Leptin Replacement Therapy Improves Insulin Resistance in Highly Active Antiretroviral Therapy (HAART) Induced Lipodystrophy and Metabolic Syndrome in.
HIV and AIDS Human Immunodeficiency Virus (HIV) causes Acquired Immune Deficiency Syndrome (AIDS)
Antiviral Agents Restricted spectrum
Changes in Lipids in Randomised, Open-Label Comparative Trial of Abacavir or Tenofovir DF as Replacement for a Thymidine Analogue in Persons with Lipoatrophy.
A Randomized Placebo- Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy Rakhi Kohli MD MS, Christine Wanke MD, Sherwood Gorbach MD,
Is HIV and AIDS the same thing? HIV “Human Immunodeficiency Syndrome” A specific type of virus (a retrovirus) HIV invades the helper T cells to replicate.
Dr.Abdul latif Mahesar. How HIVpositive differs from AIDS Does in every case HIV leads to AIDS ?
HAART Therapy Christine Ashton Christy Naylor Katherine Tompkins.
Clinical case 19 Lin, I-Yao (Sally). Case 19 Having been confined in the hospital for almost a month due recurrent pneumonia, Mr. XXX, 42 y/o, married,
AIDS. What is AIDS  Applies to the most advanced stages of HIV infection.  CDC defines AIDS as all HIV infected people who have fewer than 200 CD4 positive.
Anti-viral Drugs.. Introduction The viral agents kill viruses by inhibiting their ability to replicate, but there are currently only about a dozen such.
L-Arginine Clinical Trial Results of Study 18% increase in HDL 18% increase in HDL 40% decrease in triglycerides 40% decrease in triglycerides 8% glucose.
ARV Therapy Basics in the Context of Family Planning
Chelsea Harmon Catherine Hanson Abby Llaneza Jen Williams
A randomized open study comparing the impact of reducing stavudine dose vs. switching to tenofovir on mitochondrial function, metabolic parameters, and.
 2010 Cengage-Wadsworth Preventing Cardiovascular Disease Chapter 11.
HIV Life Cycle Step 1: Fusion Step 2: Transcription reverse transcriptase Step 3: Integration Step 4: Cleavage Step 5: Packaging and Budding HIV.
Antimicrobial drugs. Antimicrobial drugs are effective in the treatment of infections because of their selective toxicity (that is, they have the ability.
Basics of Human Immunodeficiency Virus (HIV) Brian Rybarczyk, PhD University of North Carolina- Chapel Hill.
Immune reconstitution Anjie Zhen, PhD
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
General, Organic, and Biological Chemistry Copyright © 2010 Pearson Education, Inc Viruses Chapter 21 Nucleic Acids and Protein Synthesis.
Cellular immune control of Human Immunodeficiency Virus (HIV) Dr. Ali Jalil Ali College of pharmacy.
Viro100: Virology 3 Credit hours NUST Centre of Virology & Immunology
Virology – Antivirals 2 JU- 2 nd Year Medical Students By Dr Hamed AlZoubi – Microbiology and Immunology Department – Mutah University. MBBS (J.U.S.T)
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.
Kingdome of Saudia Arabia Al-Majmaah University Applied of Medical Science Clinical Virology CLINICAL VIROLOGY MDL 325 Presented by : Mohammad Al- Turaqi.
GLYPICAN-4 LEVELS IN RELATION WITH HORMONAL AND METABOLIC PROFILE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME Doç.Dr.Özlem ALTINKAYA.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Elevated Circulating Levels of Inflammatory Markers in
HIV molecule.
Figure 6 Cholesterol metabolism in obesity-related glomerulopathy
“Sick Fat,” Metabolic Disease, and Atherosclerosis
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Human Health and Disease
What's New in Dyslipidemia?
Type 2 diabetes: Overlap of clinical conditions
Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.
Lipid Clinic Challenge
School of Pharmacy, University of Nizwa
Replication life cycle of HIV and sites of antiretroviral drug action.
Terminology HIV AIDS Acquired Human Immune Immunodeficiency Deficiency
Potential Mechanisms of Adverse Outcomes Associated with Torcetrapib
Putting Your Skills to the Test
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Louis Haenel, IV, DO Endocrinology

Terminology Lipodystrophy Lipoatrophy Lipohypertrophy HIV HAART (Highly Active Anti-Retroviral Therapy)

Facial lipoatrophy

Buffalo Hump

Peripheral Lipoatrophy

Body-Fat Abnormalities Reported in 40-50% of ambulatory HIV-infected patients Preliminary case definition by DEXA and CT imaging not ready for widespread clinical practice Central fat accumulation tends to be visceral in location

Etiology HIV – Direct virus mediated effect Protease Inhibitor Nucleoside analogue reverse-transcriptase inhibitors Nonnucleoside reverse transcriptase inhibitors Cytokine mediated effect (Adipocytokine)

Pathogenesis Inhibiting sterol regulatory enhancer- binding protein 1 (SREBP1) mediated activation of retinoid X and PPARλ Disruption of adipogenesis Inhibit mitochondrial DNA polymerase alpha (DNA replication) TNFα receptor alteration

Clinical Implications Physical changes Hypertriglyceridemia Low HDL cholesterol Modest increases in LDL cholesterol Increased diastolic BP Increased Metabolic syndrome profile Increased cardiovascular risk

Dr. Louis C. Haenel, IV Endocrinology UMDNJ-SOM Volunteer Faculty

Dyslipidemia Cholesterol elevation seen in 27% pts on combination tx (>240 mg/dl) Triglyceride elevation seen in 40% pts (>200 mg/dl) HDL <35 mg/dl seen in 27%

.

Carbohydrate Metabolism Impaired glucose tolerance seen in more than 35% of HIV infected pts compared to 5% in age and BMI matched controls DM was 3.1X as likely to develop in HIV pts treated with combination therapy vs control population

Pathogenesis ↑ circulating free fatty acids Accumulation of intramyocellular lipids Low level of adiponectin Reduced pparα activity which leads to reducing glucose transport mediated via Glut4 transporter Reduce Beta cell insulin secretion

Assessment Before initiating HIV therapy, patients should be tested for fasting blood glucose and cholesterol levels Rechecked several weeks after change in therapy and yearly Oral glucose tolerance test

Cardiovascular Disease Diabetes Mellitus is considered a coronary risk equivalent Established risk factors Hypertension is seen at higher rates in patients in HAART therapy than for age-matched controls PI therapy may promote atherosclerosis by ↑ CD-36 dependent cholesterol ester accumulation in macrophages

Risk Factor Modification Dyslipidemia Hypertension Insulin resistance Sedentary lifestyle Weight Family history Tobacco

Treatment of Lipodystrophy Change in HAART therapy Exercise Metformin Thiazolidinediones Leptin Recombinant Growth Hormone therapy Recombinant testosterone therapy Oral testosterone therapy

Treatment of Metabolic Syndrome Diet Exercise Metformin Thiazolidinediones Additional diabetes mellitus treatment strategies

Treatment of Hypertension Ace inhibitor therapy Angiotensin receptor blocker therapy Hydrochlorothiazide Beta blocker therapy

Treatment of Dyslipidemia Fibric Acid derivatives (Tricor, Lopid) Cholesterol absorption inhibitors (Zetia) Thiazolidinediones Statin therapy Pravachol Crestor Beware of Lescol, Zocor, Mevacor

Improvement of Appearance Surgery Liposuction Injectable agents Polylactic acid (promotes collagen formation)

Thyroid Infectious and Infiltrative Diseases Laboratory Medication

Infectious/Infiltrative Diseases CMV*MAI Cryptococcus*PCP Kaposi’s Sarcoma True Infection vs Postmortem Findings Inflammatory Thyroiditis

Laboratory Findings Lowered T3 Levels * 46 patients evaluated and found to have  T3 levels and normal TSH in stable HIV * T3 levels on admission correlated to mortality in 3 separate studies * T3 seems to follow typical trend seen in euthyroid sick individuals but rT3 levels remain low in asymptomatic and ill pts.

Thyroid Labs TBG levels are  with normal CBG & SHBG TSH values in stable HIV are higher on average than controls with the absolute levels in the upper limit of normal Normal pulse frequency and  amplitude Role of cytokines -- IL-6 and TNF

HIV Related Medications Rifampin (used in the treatment of MAI prophylaxis) induces hepatic microsomal enzymes and increases thyroid hormone clearance Results >  T4 (T4 replace requires  dose) normal T3  rT3 no change in TSH